Welcome to our dedicated page for STANDARD BIOTOOLS news (Ticker: LAB), a resource for investors and traders seeking the latest updates and insights on STANDARD BIOTOOLS stock.
Standard BioTools Inc. (NASDAQ: LAB) is an analytical laboratory instrument manufacturer focused on technologies that help biomedical researchers develop better medicines faster. Company news frequently highlights its standardized next-generation platforms, including SomaScan, mass cytometry and microfluidics technologies, which are used to generate reliable and repeatable insights into health and disease for translational and clinical research.
News updates for LAB commonly cover financial results and outlook, such as quarterly earnings releases and preliminary revenue announcements. These disclosures provide detail on revenue from continuing operations, trends across consumables, instruments and services, and the company’s progress toward its stated profitability goals, often accompanied by commentary on restructuring plans and cost-saving initiatives.
Another important news theme is strategic transactions and partnerships. Standard BioTools has announced a Stock Purchase Agreement with Illumina, Inc. under which Illumina will acquire SomaLogic and related assets, while Standard BioTools retains its mass cytometry and microfluidics businesses. Press releases also describe collaborations, such as work with Molecular Instruments to integrate HCR imaging technologies with the Hyperion Imaging System for next-generation Imaging Mass Cytometry workflows, and the selection of the SomaScan 11K Assay by the PRECISE-SG100K biobank for large-scale population health research.
Visitors to this LAB news page can review these company-issued updates, including information on operational restructuring, facility consolidation, workforce changes, and large biobank and population proteomics projects. Monitoring this stream of announcements can help investors and researchers understand how Standard BioTools is evolving its portfolio, managing its cost structure, and participating in the broader life sciences and multiomics ecosystem.
Standard BioTools Inc. (Nasdaq:LAB) announced it will report its second quarter 2022 financial results on August 8, 2022, after market close. The company, known for its mission to enhance human health through advanced technologies, is set to host a conference call at 1:30 p.m. PT to discuss its financial outcomes and operational progress. Interested parties can listen via phone or through a live webcast on the company's Investor Relations page.
Standard BioTools Inc. (Nasdaq:LAB) reported first-quarter 2022 financial results with total revenue of $26.5 million, down from $32.8 million in Q1 2021, primarily due to lower COVID-19 revenue. The GAAP net loss was $76.3 million, significantly higher than a net loss of $18.8 million in Q1 2021, while non-GAAP net loss also increased to $19.5 million from $11.1 million. The company secured a $250 million capital infusion from Casdin Capital and Viking Global, aimed at enhancing operations and growth strategies amidst ongoing sales disruptions and COVID-19 impacts.
Standard BioTools Inc. (Nasdaq:LAB) will announce its first quarter 2022 financial results on May 5, 2022, after market close. A conference call will be held at 2:00 p.m. PT to discuss these results and operational progress. Notably, the recent appointment of new management members follows a $250 million strategic capital infusion, leading to a 90-day assessment period without a Q&A session. The company focuses on advancing tools for biomedical research, highlighting its commitment to improving human health and efficiency in drug development.
Standard BioTools Inc. (Nasdaq:LAB) has launched the Hyperion+™ Imaging System, enhancing high-plex spatial imaging capabilities with a 1.6x lower limit of detection and the ability to process over 100 samples per week. This system enables researchers to uncover critical insights into disease mechanisms and therapeutic responses, significantly accelerating translational research. Key advantages include faster results, up to 10x cost savings compared to conventional methods, and the capacity for high-quality data generation with minimal autofluorescence. The system was unveiled at the AACR annual meeting in New Orleans.
Standard BioTools Inc. announced the grant of equity inducement awards to new executives, including Michael Egholm as CEO, Hanjoon Kim as COO, and Ardalan Arfaei as Senior VP. The Compensation Committee approved stock options and restricted stock units (RSUs) to incentivize their employment, with awards comprising millions of shares. The options have a 10-year term with an exercise price of $3.99 per share, vesting over four years. Standard BioTools aims to accelerate breakthroughs in human health using innovative technologies in biomedical research.
Summary not available.